Topic guide
Psilocybin
A structured route through psilocybin research, depression trials, microdosing claims, safety screening and UK legal context.
Start with context
Psilocybin findings are shaped by dose, setting, psychological support, participant selection, expectancy and follow-up. Results from tightly controlled studies should not be treated as instructions for unsupervised use.
Questions this topic raises
- What did the study actually compare?
- Were participants and assessors successfully blinded?
- Who was excluded on safety grounds?
- How long did any reported benefit last?
- Does research access translate into legal or routine clinical access?
Read the evidence guides
Psychedelics and Depression: Comparing the Different Research Approaches
See how population, controls, psychological support and follow-up can change the apparent result.
Microdosing Psychedelics: What Does the Evidence Actually Show?
Controlled studies, placebo effects and the limits of the evidence—without dosing advice.
Screening, Contraindications and Risk in Psychedelic Research
What clinical trials screen and monitor—and why selected study populations cannot be generalised.
Can Psychedelic Trials Really Be Blinded?
Understand functional unblinding, expectancy bias and the methods researchers use to limit them.
What Does “Psychedelic-Assisted Therapy” Really Mean?
A guide to preparation, monitored sessions, psychological support and integration.
Psychedelic Medicine and UK Law: Research, Scheduling and Access
UK drug classes, schedules, research licences and the difference between trials and routine access.
Keep the boundary clear
These guides are educational. They do not provide medical advice, personalised risk assessment, legal advice or instructions for using a controlled substance.
